Chrispictures / shutterstock.com
Massachusetts-based pharmaceutical company Akebia has had five Fibrogen patents for an anaemia treatment invalidated at the English High Court.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Akebia, Fibrogen, patent, anaemia, vadadustat, HIF-PHIs, Arnold, English High Court, Hogan Lovells, Astellas, Potter Clarkson, Carpmaels and Ransford
